Sign in
Taking people in SwedenPhase 3

Tests the order of EGFR-targeted drugs in lung cancer

Compares drug sequences in adults with EGFR-mutated non-small cell lung cancer.

Key facts

Who runs it
Region Skane
Where
Falun, Gavle, Goteborg, Kristianstad, Linkoping, Lund, Orebro, Solna, Umea, and Uppsala, SwedenSee the 10 sites
Registry title
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
Status
Recruiting
Phase
Phase 3
People taking part
200 people, planned
Started
14 Jun 2022
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
2 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with EGFR-mutated non-small cell lung cancer that cannot be treated with the aim of removing all of the disease and who have not yet had a TKI drug.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer, clinical stage III/IV or a recurrence, where treatment cannot aim to remove all of the disease. The disease must be measurable (RECIST 1.1 criteria or equivalent). Any WHO performance status.
Earlier treatment
No earlier treatment with a TKI drug.
Biomarker or test result
An EGFR mutation in the tumour. If no tumour tissue is available, circulating tumour DNA (ctDNA) in the blood plasma can be used.

Main reasons for not taking part

  • Pregnancy or refusing to use contraception
  • Stomach or gut problems that prevent swallowing or absorbing the study drug
  • Allergy to the study drug or its ingredients
  • Congenital long QT syndrome
  • A second primary cancer that can spread

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Written informed consent
  • Negative pregnancy test (blood or urine test)
  • Histological or cytological diagnosis of NSCLC
  • Clinical stage III/IV disease or a recurrence not amenable for curative treatment intention
  • Measurable disease according to RECIST 1.1 criteria or equivalent/modified criteria
  • Any WHO PS
  • Age 18 years or older
  • EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating tumour-DNA (ctDNA) in plasma may serve as inclusion criteria)
  • Treatment-naive with regard to TKI’s
  • For fertile participants, adequate contraception should be used; intrauterine device, bilateral tubal occlusion, vasectomy or abstinence (a reduced effect of hormonal contraception methods due to the drugs cannot be excluded). Pregnancy should be avoided during treatment and the first 4 months following treatment discontinuation

Who cannot take part

  • Abnormal findings of blood chemistry not compatible with the study drug according to investigator
  • Co-enrolment in other interventional trial if incompatible with ERIS according to investigator (e.g. due to potential drug interactions)
  • All subjects should avoid concomitant use of medications with known interaction with planned treatment, whenever feasible. If the administration of a medication interacts with any of the three investigational treatments and cannot be exchanged or managed in order to avoid interactions the patient is excluded from the trial
  • Condition incompatible with the study or with the planned treatment
  • Gastrointestinal conditions incompatible with swallowing or precluding absorption of the study drug
  • History of hypersensitivity to the study drug (or drugs with a similar chemical structure or class) or any excipients
  • Severe hepatic impairment/renal function incompatible with study drug according to investigator
  • Present second primary malignancy with metastatic potential
  • Any evidence of severe or uncontrolled systemic diseases which in the investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardise compliance with the protocol. Screening for chronic conditions is not required
  • Hereditary conditions with galactose intolerance, total lactase deficiency or glucose -galactose malabsorption
  • Congenital long QT syndrome
  • Pregnancy or refusal to use contraceptives
  • Judgment by the investigator that the subject should not participate in the study, e.g., if the subject is unlikely to comply with study procedures, restrictions and requirements
  • Intake of hypericum perforatum (intake must be interrupted before start of study treatment)

Where in Sweden

  • Region DalarnaFalun, SwedenTaking people
  • Region GaevleborgGavle, SwedenTaking people
  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenTaking people
  • Region Skane Kristianstad Central HospitalKristianstad, SwedenTaking people
  • Region OestergoetlandLinkoping, SwedenTaking people
  • Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people
  • Region Oerebro LaenOrebro, SwedenTaking people
  • Karolinska University HospitalSolna, SwedenTaking people
  • Region VaesterbottenUmea, SwedenTaking people
  • Uppsala University HospitalUppsala, SwedenTaking people

About the trial

What the trial wants to find out

To evaluate the optimal sequence of EGFR-inhibitors.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
Plain-language title
Tests the order of EGFR-targeted drugs in lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 December 2024